Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

CompletedOBSERVATIONAL
Enrollment

281

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Advanced Renal Cell Carcinoma (aRCC)
Trial Locations (9)

G12 0XH

Beatson West of Scotland Cancer Centre, Glasgow

GU2 7XX

Royal Surrey County Hospital, Guildford

E1 2ES

Barts Cancer Institute, London

SW3 6JJ

Royal Marsden Hospital, London

M20 4BX

Christie NHS Foundation Trust, Manchester

CH63 4JY

Clatterbridge Road, Bebington, Metropolitan Borough of Wirral

NG5 1PB

Nottingham University Hospital, Nottingham

PR2 9HT

Royal Preston Hospital, Preston

AL8 6JL

Mount Vernon Cencer Centre, Welwyn Garden City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY